A natural small molecule voacangine inhibits angiogenesis both in vitro and in vivo

Yonghyo Kim; Hye Jin Jung; Ho Jeong Kwon

doi:10.1016/j.bbrc.2011.11.109

A natural small molecule voacangine inhibits angiogenesis both in vitro and in vivo

Yonghyo Kim, Hye Jin Jung, Ho Jeong Kwon

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

Angiogenesis, the formation of new blood vessels from pre-existing ones, plays a critical role in normal and pathological phenotypes, including solid tumor growth and metastasis. Accordingly, the development of new anti-angiogenic agents is considered an efficient strategy for the treatment of cancer and other human diseases linked with angiogenesis. We have identified voacangine, isolated from Voacanga africana, as a novel anti-angiogenic agent. Voacangine inhibits the proliferation of HUVECs at an IC ₅₀ of 18μM with no cytotoxic effects. Voacangine significantly suppressed in vitro angiogenesis, such as VEGF-induced tube formation and chemoinvasion. Moreover, the compound inhibits in vivo angiogenesis in the chorioallantoic membrane at non-toxic doses. In addition, voacangine decreased the expression levels of hypoxia inducible factor-1α and its target gene, VEGF, in a dose-dependent manner. Taken together, these results suggest that the naturally occurring compound, voacangine, is a novel anti-angiogenic compound.

Original language	English
Pages (from-to)	330-334
Number of pages	5
Journal	Biochemical and Biophysical Research Communications
Volume	417
Issue number	1
DOIs	https://doi.org/10.1016/j.bbrc.2011.11.109
Publication status	Published - 2012 Jan 6

Bibliographical note

Funding Information:
This study was partly supported by grants from the National Research Foundation of Korea funded by the Korean Government (MEST; 2009-0092964, 2010-0017984, F01-2009-000-10183-0), the Translational Research Center for Protein Function Control, KRF (2009-0083522), the Center for Food and Drug Materials of Agriculture Science & Technology Development (2011-8-1178), Rural Development Administration, National R&D Program, Ministry of Health & Welfare, and the Brain Korea 21 Project, Republic of Korea.

All Science Journal Classification (ASJC) codes

Biophysics
Biochemistry
Molecular Biology
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bbrc.2011.11.109

Cite this

@article{2919588759274ff8be524d744d44b634,

title = "A natural small molecule voacangine inhibits angiogenesis both in vitro and in vivo",

abstract = "Angiogenesis, the formation of new blood vessels from pre-existing ones, plays a critical role in normal and pathological phenotypes, including solid tumor growth and metastasis. Accordingly, the development of new anti-angiogenic agents is considered an efficient strategy for the treatment of cancer and other human diseases linked with angiogenesis. We have identified voacangine, isolated from Voacanga africana, as a novel anti-angiogenic agent. Voacangine inhibits the proliferation of HUVECs at an IC 50 of 18μM with no cytotoxic effects. Voacangine significantly suppressed in vitro angiogenesis, such as VEGF-induced tube formation and chemoinvasion. Moreover, the compound inhibits in vivo angiogenesis in the chorioallantoic membrane at non-toxic doses. In addition, voacangine decreased the expression levels of hypoxia inducible factor-1α and its target gene, VEGF, in a dose-dependent manner. Taken together, these results suggest that the naturally occurring compound, voacangine, is a novel anti-angiogenic compound.",

author = "Yonghyo Kim and Jung, {Hye Jin} and Kwon, {Ho Jeong}",

note = "Funding Information: This study was partly supported by grants from the National Research Foundation of Korea funded by the Korean Government (MEST; 2009-0092964, 2010-0017984, F01-2009-000-10183-0), the Translational Research Center for Protein Function Control, KRF (2009-0083522), the Center for Food and Drug Materials of Agriculture Science & Technology Development (2011-8-1178), Rural Development Administration, National R&D Program, Ministry of Health & Welfare, and the Brain Korea 21 Project, Republic of Korea.",

year = "2012",

month = jan,

day = "6",

doi = "10.1016/j.bbrc.2011.11.109",

language = "English",

volume = "417",

pages = "330--334",

journal = "Biochemical and Biophysical Research Communications",

issn = "0006-291X",

publisher = "Academic Press Inc.",

number = "1",

}

TY - JOUR

T1 - A natural small molecule voacangine inhibits angiogenesis both in vitro and in vivo

AU - Kim, Yonghyo

AU - Jung, Hye Jin

AU - Kwon, Ho Jeong

N1 - Funding Information: This study was partly supported by grants from the National Research Foundation of Korea funded by the Korean Government (MEST; 2009-0092964, 2010-0017984, F01-2009-000-10183-0), the Translational Research Center for Protein Function Control, KRF (2009-0083522), the Center for Food and Drug Materials of Agriculture Science & Technology Development (2011-8-1178), Rural Development Administration, National R&D Program, Ministry of Health & Welfare, and the Brain Korea 21 Project, Republic of Korea.

PY - 2012/1/6

Y1 - 2012/1/6

N2 - Angiogenesis, the formation of new blood vessels from pre-existing ones, plays a critical role in normal and pathological phenotypes, including solid tumor growth and metastasis. Accordingly, the development of new anti-angiogenic agents is considered an efficient strategy for the treatment of cancer and other human diseases linked with angiogenesis. We have identified voacangine, isolated from Voacanga africana, as a novel anti-angiogenic agent. Voacangine inhibits the proliferation of HUVECs at an IC 50 of 18μM with no cytotoxic effects. Voacangine significantly suppressed in vitro angiogenesis, such as VEGF-induced tube formation and chemoinvasion. Moreover, the compound inhibits in vivo angiogenesis in the chorioallantoic membrane at non-toxic doses. In addition, voacangine decreased the expression levels of hypoxia inducible factor-1α and its target gene, VEGF, in a dose-dependent manner. Taken together, these results suggest that the naturally occurring compound, voacangine, is a novel anti-angiogenic compound.

AB - Angiogenesis, the formation of new blood vessels from pre-existing ones, plays a critical role in normal and pathological phenotypes, including solid tumor growth and metastasis. Accordingly, the development of new anti-angiogenic agents is considered an efficient strategy for the treatment of cancer and other human diseases linked with angiogenesis. We have identified voacangine, isolated from Voacanga africana, as a novel anti-angiogenic agent. Voacangine inhibits the proliferation of HUVECs at an IC 50 of 18μM with no cytotoxic effects. Voacangine significantly suppressed in vitro angiogenesis, such as VEGF-induced tube formation and chemoinvasion. Moreover, the compound inhibits in vivo angiogenesis in the chorioallantoic membrane at non-toxic doses. In addition, voacangine decreased the expression levels of hypoxia inducible factor-1α and its target gene, VEGF, in a dose-dependent manner. Taken together, these results suggest that the naturally occurring compound, voacangine, is a novel anti-angiogenic compound.

UR - http://www.scopus.com/inward/record.url?scp=84855821639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855821639&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2011.11.109

DO - 10.1016/j.bbrc.2011.11.109

M3 - Article

C2 - 22155252

AN - SCOPUS:84855821639

SN - 0006-291X

VL - 417

SP - 330

EP - 334

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

IS - 1

ER -

A natural small molecule voacangine inhibits angiogenesis both in vitro and in vivo

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this